M. Huff Gary Purchases 31,250 Shares of Biomerica (NASDAQ:BMRA) Stock

Biomerica, Inc. (NASDAQ:BMRA) Director M. Huff Gary acquired 31,250 shares of Biomerica stock in a transaction that occurred on Thursday, August 20th. The stock was bought at an average cost of $1.60 per share, with a total value of $50,000.00. Following the acquisition, the director directly owned 51,250 shares of the company’s stock, valued at approximately $82,000. This trade represents a 156.25% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Biomerica Stock Up 1.9%

Shares of BMRA opened at $2.14 on Friday. The firm has a 50-day moving average price of $1.67 and a 200 day moving average price of $1.99. The firm has a market capitalization of $6.61 million, a PE ratio of -2.40 and a beta of 0.35. Biomerica, Inc. has a 52-week low of $1.45 and a 52-week high of $3.22.

Institutional Investors Weigh In On Biomerica

An institutional investor recently raised its stake in Biomerica stock. DRW Securities LLC raised its holdings in Biomerica, Inc. (NASDAQ:BMRA) by 62.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,925 shares of the company’s stock after acquiring an additional 6,533 shares during the quarter. DRW Securities LLC owned 0.56% of Biomerica worth $43,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 22.28% of the company’s stock.

Analyst Ratings Changes

BMRA has been the topic of a number of research analyst reports. Weiss Ratings lowered shares of Biomerica from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, June 5th. Citizens Jmp initiated coverage on Biomerica in a research report on Tuesday, May 5th. They issued a “mkt outperform” rating and a $9.00 target price for the company. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell” and a consensus price target of $9.00.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.